Responses

Download PDFPDF

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    The site distribution of gastrointestinal carcinoids differs between races
    • Tsuyoshi Konishi
    • Other Contributors:
      • Toshiaki Watanabe, Tetsuichiro Muto, Kenjiro Kotake, and Hirokazu Nagawa, on behalf of the Japanese Society for Cancer of the Colon and Rectum

    Dear Editor,

    We read with great interest the guideline for gastroenteropancreatic neuroendocrine (including carcinoid) tumors by Ramage et al.[1] In this excellent guideline, they reported that appendix is the most frequent site of gastrointestinal primary endocrine tumors, consisting 35% of the total tumors, while colon and rectal carcinoids consisted only 7% and 10%, respectively. One important aspect not ment...

    Show More
    Conflict of Interest:
    None declared.